WESPAC Advisors SoCal’s Trinity Biotech TRIB Stock Holding History

WESPAC Advisors SoCal’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,040	Closed	-$14K	–	281
2019 Q1	$14K	Hold	1,040	–	–	0.01%	206
2018 Q4	$11K	Hold	1,040	–	–	0.01%	233
2018 Q3	$20K	Buy	+1,040	New	+$22.6K	0.01%	188
2018 Q2	–	Sell	-1,040	Closed	-$26K	–	238
2018 Q1	$26K	Hold	1,040	–	–	0.02%	144
2017 Q4	$26K	Hold	1,040	–	–	0.01%	146
2017 Q3	$29K	Hold	1,040	–	–	0.02%	141
2017 Q2	$31K	Hold	1,040	–	–	0.02%	132
2017 Q1	$31K	Hold	1,040	–	–	0.02%	131
2016 Q4	$36K	Hold	1,040	–	–	0.02%	123
2016 Q3	$68.7K	Hold	1,040	–	–	0.05%	105
2016 Q2	$59K	Hold	1,040	–	–	0.04%	114
2016 Q1	$60.6K	Hold	1,040	–	–	0.04%	110
2015 Q4	$61K	Buy	+1,040	New	+$61.4K	0.04%	115

Other funds holding TRIB

SCM

Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

ARM

Adirondack Research & Management Guilderland, New York $82.2M AUM 63.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WESPAC Advisors SoCal's TRIB Position: Q2 2019 in Review

WESPAC Advisors SoCal sold out of Trinity Biotech (TRIB) in Q2 2019, closing a stake of 1,040 shares — an estimated $14K sold.

WESPAC Advisors SoCal first reported a position in TRIB in Q4 2015 and held it in 13 quarters. The position peaked at $68.7K in Q3 2016. 35 funds tracked by Wall St. Rank hold TRIB as of Q2 2019.

WESPAC Advisors SoCal reported no remaining Trinity Biotech position as of Q2 2019 after selling out during the quarter.
WESPAC Advisors SoCal sold 1,040 Trinity Biotech shares in Q2 2019, an estimated $14K.
WESPAC Advisors SoCal first reported a position in Trinity Biotech in Q4 2015 and held it in 13 quarters.
WESPAC Advisors SoCal's Trinity Biotech position peaked at $68.7K in Q3 2016.
35 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2019.

Based on WESPAC Advisors SoCal's 13F filing for Q2 2019, filed 30 Jul 2019.